• user warning: Table './fnndrupaldev/term_node' is marked as crashed and last (automatic?) repair failed query: SELECT t.* FROM term_node r INNER JOIN term_data t ON r.tid = t.tid INNER JOIN vocabulary v ON t.vid = v.vid WHERE r.vid = 500660 ORDER BY v.weight, t.weight, t.name in /var/www/www.fnno.com/htdocs/modules/taxonomy/taxonomy.module on line 617.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT COUNT(sid) AS count FROM sessions WHERE timestamp >= 1419189257 AND uid = 0 in /var/www/www.fnno.com/htdocs/includes/session.inc on line 111.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT DISTINCT u.uid, u.name, s.timestamp FROM users u INNER JOIN sessions s ON u.uid = s.uid WHERE s.timestamp >= 1419189257 AND s.uid > 0 ORDER BY s.timestamp DESC in /var/www/www.fnno.com/htdocs/modules/user/user.module on line 765.

AEterna Zentaris Up 6.6%, Shares Break Through Resistance (AEZS)

Published on Thu, 05/16/2013 - 12:25
By Peter Chu

AEterna Zentaris (NASDAQ:AEZS) is one of today's best performing low-priced stocks, up 6.6% to $2.08 on 2.8x average daily volume. Thus far today, AEterna Zentaris has traded 568,000 shares, vs. average volume of 204,000 shares per day. The stock has outperformed the Dow (6.6% to the Dow's 0.1%) and outperformed the S&P 500 (6.6% to the S&P's -0.0%) during today's trading.

Over the past year, AEterna Zentaris has traded in a range of $1.70 to $5.63 and is now at $2.08, 22% above that low. Over the past week, the 200-day moving average (MA) has gone down 0.5% while the 50-day MA has declined 1.7%.

There is potential upside of 73.2% for shares of AEterna Zentaris based on a current price of $2.08 and an average consensus analyst price target of $3.60. The stock should hit resistance at its 200-day moving average (MA) of $2.50, as well as support at its 50-day MA of $1.91.

AEterna Zentaris Inc is a biopharmaceutical company focused in oncology and endocrine therapy. The Company's portfolio includes an orally-active inhibitor for multiple cancers, as well a product marketed for in vitro fertilization. AEterna Zentaris also develops and sells active ingredients, specialty chemicals, cosmetic, and nutritional products.

By Peter Chu
pchu@fnno.com

Latest News from FNNO

Earnings Look Back: Genesco Is Up 5.1% S...

When Genesco (NYSE:GCO) reported earnings two weeks ago on December 5th, 2014, analysts ...

Post Earnings Update: Vail Resorts Has C...

12 days ago, on December 8th, 2014, Vail Resorts (NYSE:MTN) reported its earnings. Ana ...

Cantel Medical Earnings Review: 10 Days ...

10 days ago, on December 10th, 2014, Cantel Medical (NYSE:CMN) reported its earnings. ...

ABM Industries Earnings Review: 12 Days ...

12 days ago, on December 8th, 2014, ABM Industries (NYSE:ABM) reported its earnings. A ...

Post Earnings Update: Gildan Activewear ...

Two weeks ago on December 4th, 2014 Gildan Activewear (NYSE:GIL) reported earnings and ...

Earnings Look Back: Christopher & Banks ...

When Christopher & Banks (NYSE:CBK) reported earnings two weeks ago on December 4th, 20 ...

Post Earnings Update: Methode Electronic...

9 days ago, on December 11th, 2014, Methode Electronics (NYSE:MEI) reported its earning ...

Phillips-Van Heusen Earnings In Retrospe...

Two weeks ago on December 3rd, 2014 Phillips-Van Heusen (NYSE:PVH) reported earnings an ...